Myeloablative and Reduced Intensity Allogeneic Transplant in Patients with Myeloproliferative Neoplasms
For MF and CMML, older patients (≥65) and RIC transplants trended toward worse survival. Strategies to reduce relapse and optimize patient selection utilizing molecular and cytogenetic data should be considered.
Authors
- Ronald Sobecks (ORCID: https://orcid.org/0000-0003-1608-3261)
- Hetty E. Carraway (ORCID: https://orcid.org/0000-0001-5241-3614)
- Aaron T. Gerds (ORCID: https://orcid.org/0000-0002-3422-1309)
- Craig S. Sauter (ORCID: https://orcid.org/0000-0002-5316-8785)
- Akriti Gupta Jain (ORCID: https://orcid.org/0000-0002-7238-9241)
- Andrew D. Trunk (ORCID: https://orcid.org/0000-0001-8961-4639)
- Claudio G. Brunstein (ORCID: https://orcid.org/0000-0002-1997-3799)
- Betty K. Hamilton (ORCID: https://orcid.org/0000-0003-1252-6539)
- Sophia Balderman (ORCID: https://orcid.org/0000-0001-8157-8725)
- Yanwen Chen (ORCID: https://orcid.org/0000-0002-3467-2871)
- Sudipto Mukherjee (ORCID: https://orcid.org/0000-0002-8325-2603)
- Matt Kalaycio
Institutions
- Cleveland Clinic (US)
Publication Details
- Journal
- Hematology/Oncology and Stem Cell Therapy
- Published
- 2025-09-12
- DOI
- https://doi.org/10.4103/hemoncstem.hemoncstem-d-25-00008
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00